New Orleans—It’s been said that the best treatment for low-risk prostate cancer is no treatment at all. A number of studies at the 2015 AUA annual meeting appeared to bear that out, showing active surveillance to be a safe and increasingly common approach in this patient population.
The meeting’s “Crossfire: Controversies in Urology” was a highlight for the second year in a row, with debates about whether shock wave lithotripsy should be retired and whether focal therapy for prostate cancer is hope or hype drawing big crowds.
Abstracts comparing surgical techniques, including robotic techniques, were hot, as were studies on new treatments for BPH, the use of mesh in pelvic organ prolapse, and the safety of testosterone replacement therapy.
Urology Times’ “Best of AUA 2015” report provides a guide to the meeting’s take-home messages in 15 therapeutic areas—an information-packed, condensed summary of the top papers and presentations. The editors’ choices for high-interest messages are highlighted in boldface type.
Click below to jump a disease state: